12 October, 2020
Skadden advised Shanghai-based JHBP (CY) Holdings Limited ("Genor Biopharma"), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, on its listing and initial public offering on the Main Board of the Hong Kong Stock Exchange. Genor Biopharma offered an aggregate of almost 119.9 million shares at a price of HK$ 24 per share for a total offering value of HK$ 2.87 billion (US$ 371 million). The public offering was oversubscribed 1,247 times, making it one of the most sought after biotech IPOs in Hong Kong this year. Trading commenced 7 October 2020.
The Skadden team was led by Hong Kong partners Julie Gao, Christopher Betts, and Paloma Wang, with Counsel Yuting Wu (Shanghai), Hong Kong associates Martina To, Nicole Yuen, and Lu Ma, international legal consultant Luwei Wang (Shanghai), and trainee solicitors Nicholas Poon (Hong Kong) and Nigel Pang (Hong Kong).
